Eleven-year management of prostate cancer patients on active surveillance: what have we learned?

Published on Jun 14, 2017in Tumori1.707
· DOI :10.5301/TJ.5000649
C. Marenghi6
Estimated H-index: 6
Maria Francesca Alvisi5
Estimated H-index: 5
+ 31 AuthorsRiccardo Valdagni51
Estimated H-index: 51
(University of Milan)
PurposeTo evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate cancer (PCa) and to identify predictors of disease reclassification.MethodsIn 2005, we defined an inst...
📖 Papers frequently viewed together
16 Citations
12 Authors (Koji Mitsuzuka, ..., Yoichi Arai)
34 Citations
109 Citations
#1Claudia Repetto (CUA: The Catholic University of America)H-Index: 17
#2Tiziana RancatiH-Index: 27
Last. Lara BellarditaH-Index: 10
view all 14 authors...
PurposeTo investigate the presence of regret in patients about having followed an active surveillance (AS) protocol. The secondary aim was to identify variables that influence regret.MethodsFrom February 2006 to May 2014, 204 patients discontinued the AS protocols and were invited to enter the study. Sociodemographic variables were collected at AS enrollment, together with health-related quality of life (Functional Assessment of Cancer Therapy-Prostate version [FACT-P]) and coping (Mini-Mental A...
3 CitationsSource
#1James L. Mohler (OSU: Ohio State University)H-Index: 1
#2Andrew J. Armstrong (OSU: Ohio State University)H-Index: 63
Last. Deborah A. Freedman-Cass (OSU: Ohio State University)H-Index: 27
view all 32 authors...
Abstract The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which in...
428 CitationsSource
#1Jeffrey J. Tosoian (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 29
#2Mufaddal Mamawala (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 13
Last. H. Ballentine Carter (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 79
view all 7 authors...
PurposeTo assess long-term outcomes of men with favorable-risk prostate cancer in a prospective, active-surveillance program.MethodsCurative intervention was recommended for disease reclassification to higher cancer grade or volume on prostate biopsy. Primary outcomes were overall, cancer-specific, and metastasis-free survival. Secondary outcomes were the cumulative incidence of reclassification and curative intervention. Factors associated with grade reclassification and curative intervention w...
316 CitationsSource
#1Lara BellarditaH-Index: 10
#2Riccardo ValdagniH-Index: 51
Last. Ida J. Korfage (Erasmus University Medical Center)H-Index: 36
view all 8 authors...
Abstract Context The optimal management of screen-detected, localised prostate cancer remains controversial, related to overtreatment issues of screening and the nonrandomised evidence base. Active surveillance (AS) aims to delay or avoid curative therapy but may potentially harm patients' well-being through living with untreated prostate cancer. Objective To systematically review the literature on quality of life (QoL) in patients undergoing AS. Evidence acquisition Embase, Medline, Psychinfo, ...
87 CitationsSource
#1Christopher J. Welty (UCSF: University of California, San Francisco)H-Index: 12
#1Christopher J. Welty (UCSF: University of California, San Francisco)H-Index: 8
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 11 authors...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatment in men with low risk prostate cancer. We report updated outcomes from a long-standing active surveillance cohort and factors associated with reclassification.Materials and Methods: We retrospectively reviewed data on all men enrolled in the active surveillance cohort at our institution with at least 6 months of followup between 1990 and 2013. Surveillance consisted of quarterly prostate specific...
109 CitationsSource
#1Laurence Klotz (U of T: University of Toronto)H-Index: 85
#2Danny Vesprini (U of T: University of Toronto)H-Index: 33
Last. Andrew Loblaw (U of T: University of Toronto)H-Index: 35
view all 9 authors...
Purpose Active surveillance is increasingly accepted as a treatment option for favorable-risk prostate cancer. Long-term follow-up has been lacking. In this study, we report the long-term outcome of a large active surveillance protocol in men with favorable-risk prostate cancer. Patients and Methods In a prospective single-arm cohort study carried out at a single academic health sciences center, 993 men with favorable- or intermediate-risk prostate cancer were managed with an initial expectant a...
692 CitationsSource
#1Elizabeth Selvadurai (ICR: Institute of Cancer Research)H-Index: 2
#2Mausam Singhera (ICR: Institute of Cancer Research)H-Index: 3
Last. Chris Parker (ICR: Institute of Cancer Research)H-Index: 83
view all 9 authors...
Abstract Background Active surveillance (AS) aims to allow men with favourable-risk, localised prostate cancer to avoid unnecessary treatment. Objective To describe the clinical outcomes of a prospective study of AS. Design, setting, and participants A single-centre, prospective cohort study. Eligibility criteria included histologically proven prostate adenocarcinoma, age 50–80 yr, stage T1/T2, prostate-specific antigen level (PSA) 65 yr), and percent positive biopsy cores (PPC) ≤50%. Interventi...
161 CitationsSource
#1David Margel (UHN: University Health Network)H-Index: 24
#2Indrani Nandy (RTP: Research Triangle Park)H-Index: 7
Last. Neil Fleshner (UHN: University Health Network)H-Index: 73
view all 5 authors...
Purpose: We identify risk factors for pathological progression among men on active surveillance in the REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management trial).Materials and Methods: REDEEM was a 3-year, randomized, double-blind study of patients in 65 North American academic centers. Eligible men were 48 to 82 years old, with low risk prostate cancer (T1c–T2a), Gleason score 6 or less, 3 or fewer cores positive, tumor less than 50% of any 1 core, serum pros...
15 CitationsSource
#1Anna Bill-Axelson (Uppsala University)H-Index: 27
#2Hans GarmoH-Index: 57
Last. Jennifer R. Rider (Harvard University)H-Index: 28
view all 8 authors...
Abstract Background Studies enumerating the dynamics of physical and emotional symptoms following prostate cancer (PCa) treatment are needed to guide therapeutic strategy. Yet, overcoming patient selection forces is a formidable challenge for observational studies comparing treatment groups. Objective To compare patterns of symptom burden and distress in men with localized PCa randomized to radical prostatectomy (RP) or watchful waiting (WW) and followed up longitudinally. Design, setting, and p...
60 CitationsSource
#1Jeffrey J. Tosoian (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 29
#2Eric A. JohnBull (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 4
Last. H. Ballentine Carter (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 79
view all 8 authors...
Purpose: We assessed oncologic outcomes at surgery in men with low risk and very low risk prostate cancer who were candidates for active surveillance.Materials and Methods: In a prospectively collected institutional database, we identified 7,486 subjects eligible for active surveillance who underwent radical retropubic prostatectomy. Candidates were designated as being at low risk (stage T1c/T2a, prostate specific antigen 10 ng/ml or less, and Gleason score 6 or less) or very low risk (stage T1c...
77 CitationsSource
Cited By9
#1Paolo GandelliniH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 16 authors...
Active surveillance (AS) has evolved as a strategy alternative to radical treatments for very low risk and low-risk prostate cancer (PCa). However, current criteria for selecting AS patients are still suboptimal. Here, we performed an unprecedented analysis of the circulating miRNome to investigate whether specific miRNAs associated with disease reclassification can provide risk refinement to standard clinicopathological features for improving patient selection. The global miRNA expression profi...
#1Glenda Kith (UCSF: University of California, San Francisco)H-Index: 2
#2Sarah Lisker (UCSF: University of California, San Francisco)H-Index: 3
Last. Nynikka R. Palmer (UCSF: University of California, San Francisco)H-Index: 12
view all 6 authors...
Abstract Context Evidence-based guidelines for active surveillance (AS), a treatment option for men with low-risk prostate cancer, recommend regular follow-up at periodic intervals to monitor disease progression. However, gaps in monitoring can lead to delayed detection of cancer progression, leading to a missed window of curability. Objective We aimed to identify the extent to which real-world observational studies reported adherence to monitoring protocols among prostate cancer patients on AS....
3 CitationsSource
#1Paola DordoniH-Index: 6
#1Paola DordoniH-Index: 2
Last. Lara BellarditaH-Index: 10
view all 11 authors...
OBJECTIVE: To investigate whether prostate cancer (PCa) patients' coping strategies (i.e., fighting spirit, anxious preoccupation, fatalism, helplessness/hopelessness, and avoidance) significantly change during the first 3-year follow-up period of active surveillance (AS). MATERIALS AND METHODS: Altogether, 104 patients on AS completed the Mini-Mental Adjustment to Cancer (Mini-MAC) at baseline (T0), at 10 and 12 months after diagnostic biopsy (T1 and T2, respectively) and then at 24- (T3) and 3...
2 CitationsSource
Background The psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e., re-biopsy, prostate-specific antigen (PSA) test, and medical examination]. Even if it is known from the literature that the majority of PCa men in AS do not report heightened anxiety, there is a minority of patients who show clinically significan...
#1Julia Wade (UoB: University of Bristol)H-Index: 15
#2Jenny L Donovan (UoB: University of Bristol)H-Index: 106
Last. Edgar PaezH-Index: 6
view all 24 authors...
Objectives Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men’s strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supp...
3 CitationsSource
#1Luke Witherspoon (U of O: University of Ottawa)H-Index: 5
#2Rodney H. Breau (Ottawa Hospital Research Institute)H-Index: 28
Last. Luke T. Lavallée (Ottawa Hospital Research Institute)H-Index: 16
view all 3 authors...
Active surveillance is a good management option for some men with non-metastatic prostate cancer. In this review, we examine the evidence for several topics related to active surveillance. We examine: (1) which patients should be eligible for active surveillance, (2) what follow-up (monitoring) protocols should be used for men on surveillance, (3) what is the role of prostate magnetic resonance imaging (MRI) for men on surveillance, and (4) what is the prognosis for men who choose surveillance c...
3 CitationsSource
#1Julia Menichetti (University of Oslo)H-Index: 9
#2Letizia De LucaH-Index: 2
Last. Lara BellarditaH-Index: 10
view all 7 authors...
OBJECTIVE: Health promotion is a key aspect for health outcomes of prostate cancer (PCa) patients. However, it has been poorly explored among patients following monitoring programmes, for example Active Surveillance (AS). This study aimed to explore PCa patients' perceptions of health promotion during AS. METHODS: An explorative qualitative research design was adopted. Four focus groups were used to collected data from 24 men enrolled in the Prostate Cancer Research International: AS (PRIAS) pro...
1 CitationsSource
#1Paolo GandelliniH-Index: 25
#2Nicola Casiraghi (University of Trento)H-Index: 7
Last. Nadia ZaffaroniH-Index: 66
view all 11 authors...
Abstract Background Genomic characterization of prostate cancer (PCa) biopsies may improve criteria for the selection of patients suitable for active surveillance (AS). Objective To identify somatic genomic aberrations associated with adverse outcome as AS protocol exclusion indicators. Design, setting and participants Whole-exome sequencing profiles were generated for Gleason score (GS) = 3 + 3 biopsies obtained from 54 PCa patients enrolled in two AS protocols. Patients were selected as repres...
1 CitationsSource
#1Saranya Prathibha (OSU: Ohio State University)H-Index: 1
#2K. G. Goyal (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 3
Last. Debra L. Zynger (OSU: Ohio State University)H-Index: 24
view all 3 authors...
Summary Extended prostate needle core biopsies are standard of care for the diagnosis of prostatic carcinoma. Subsequent biopsies may be performed for a variety of indications. Knowledge of biopsy characteristics indicating risk for progression may have utility to guide therapeutic management. Prostate needle core biopsies performed between 2008 and 2014 were reviewed. Patients with at least 1 subsequent biopsy were identified. Cases were categorized by worst initial diagnosis. Gleason ≤6 carcin...
1 CitationsSource
#1Netty KinsellaH-Index: 4
#2Jozien Helleman (Erasmus University Medical Center)H-Index: 19
Last. Mieke Van HemelrijckH-Index: 36
view all 7 authors...
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk prostate cancer (PC), however there is discordance amongst large AS cohort studies with respect to entry and monitoring protocols. We systematically reviewed worldwide AS practices in studies reporting ≥5 years follow-up. We searched PubMed and Medline 2000-now and identified 13 AS cohorts. Three key areas were identified: (I) patient selection; (II) monitoring protocols; (III) triggers for intervention...
39 CitationsSource